SVB Wealth LLC Has $52,000 Stock Position in Amarin Co. plc (NASDAQ:AMRN)

SVB Wealth LLC increased its holdings in shares of Amarin Co. plc (NASDAQ:AMRN) by 100.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 60,000 shares of the biopharmaceutical company’s stock after acquiring an additional 30,000 shares during the quarter. SVB Wealth LLC’s holdings in Amarin were worth $52,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMRN. China Universal Asset Management Co. Ltd. raised its position in shares of Amarin by 351.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 44,599 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 34,725 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Amarin by 16.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 122,498 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 17,613 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. increased its holdings in Amarin by 18.9% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 129,200 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 20,500 shares in the last quarter. Hayek Kallen Investment Management raised its stake in shares of Amarin by 83.6% in the 3rd quarter. Hayek Kallen Investment Management now owns 622,643 shares of the biopharmaceutical company’s stock valued at $573,000 after purchasing an additional 283,564 shares during the period. Finally, Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Amarin by 35.7% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 649,152 shares of the biopharmaceutical company’s stock valued at $597,000 after purchasing an additional 170,670 shares in the last quarter. 22.25% of the stock is currently owned by institutional investors.

Amarin Price Performance

Amarin stock opened at $0.88 on Wednesday. The firm has a 50-day moving average of $0.99 and a 200-day moving average of $0.93. The company has a market cap of $362.74 million, a price-to-earnings ratio of -6.31 and a beta of 1.98. Amarin Co. plc has a one year low of $0.65 and a one year high of $1.49.

Amarin (NASDAQ:AMRN) last posted its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.04. Amarin had a negative return on equity of 10.47% and a negative net margin of 19.26%. The firm had revenue of $74.71 million during the quarter, compared to the consensus estimate of $72.46 million. As a group, sell-side analysts expect that Amarin Co. plc will post -0.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Amarin in a report on Friday, January 12th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $1.08.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.